Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Morgan Stanley analyst Cecilia Furlong maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $10...
RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:MDT) with a Outperform and raises the price target from $111 to $...
Medtronic PLC's stock rose on strong Q2 results, driven by high demand in cardiovascular and diabetes businesses. Analysts ...
UBS analyst Danielle Antalffy maintains Medtronic (NYSE:MDT) with a Neutral and raises the price target from $95 to $102.
Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $100 t...
Baird analyst David Rescott maintains Medtronic (NYSE:MDT) with a Neutral and raises the price target from $103 to $109.
Goldman Sachs analyst David Roman upgrades Medtronic (NYSE:MDT) from Sell to Neutral and raises the price target from $81 to...
